Eprex - agent
stimulates the formation of red blood cells.
The pharmacological properties of Eprex
By the nature of Eprex epoetin alfa is a glycoprotein obtained by genetic engineering. It belongs to the pharmacological agents that stimulate the formation of red blood cells - red blood cells, and is different in properties from human erythropoietin.
The mechanism of action of the drug is that it stimulates the division and differentiation of erythrocyte precursor. This effect was selective, not affecting, for example, the formation of white blood cells - leukocytes. Studies have proven that Eprex has little ability to induce the formation of antibodies to it.
There is no evidence that Eprex has teratogenic or carcinogenic properties.
The drug is produced in glass syringes as a solution for injection.
Indications for use Eprex
Eprex is used in the treatment of anemia in children and adults with chronic renal failure in people with non-myeloid cancer pathology origin (including for the prevention of anemia), in the case of anemia in people infected with HIV and receiving zidovudine treatment.
If surgery is planned with extensive blood loss in adults against the background of anemia mild or moderate severity, for the prevention of extensive blood transfusions in the future and restore the normal rate of formation of red blood cells, is used Eprex.
Do not use Eprex intolerance components, unregulated hypertension, marked the defeat of vessels of the heart, the brain, including patients who have recently had a heart attack or stroke. Pregnancy and breast-feeding, as well as the inability to carry out adequately prevent blood clots are also a contraindication to Eprex.
If a patient with partial red cell aplasia received treatment of any erythropoietin use Eprex had not recommended.
Instructions for use Eprex
The drug is in a sterile disposable syringe, it is intended for subcutaneous or intravenous administration.
Before use, be sure to verify the absence of visible particles in the liquid. The syringe should not be shaken - this can destroy the structure of epoetin alfa.
Intravenous administration is for at least 1-5 minutes. Eprex should not be mixed with other drugs or administered as an intravenous infusion.
When the amount of subcutaneous administration of infusion should not exceed 1 ml, in the event of excess must enter the drug in a few places. Usually subcutaneous choose hip, shoulder, abdominal wall.
During the course of drug therapy should be to achieve an optimal level of hemoglobin 120 g / l (for either sex) and not exceed it. During treatment, you need to check the level of serum iron in the blood and when it falls to the treatment add iron supplements.
Eprex is prescribed for diseases related anemia, and to prevent its occurrence during the course of chemotherapy, if during the first year it decreased hemoglobin more than 20 g / l. The starting dose of Eprex is 150 IU / kg 3 times a week or 40 000ME 1 time per week.
If after four weeks of treatment the patient hemoglobin rose to 10g / l or more, and analyzing reticulocytes in at least 40 000 in 1 mm, it confirms the correctness of the selected dose. If fewer targets these figures, the dose for the next 4 weeks must be increased to 300 IU / kg three times a week or 60 1 000 IU weekly.
If this dose after 4 weeks of treatment achieved sufficient increase in hemoglobin and reticulocytes, the dosage is deemed sufficient, and it stops. If the increase in hemoglobin and reticulocytes increased at less than the recommended dose of numbers, the treatment was stopped.
If the increase in hemoglobin is greater than 20 g / l for a month or achieve the desired level of 120 g / L, the dose of Eprex should be reduced by 25%. The excess hemoglobin blood 120 g / l treatment with epoetin alfa for a time suspended, and resumed after reduction of hemoglobin below 120 g / l at a dosage 25% less than the original. Introduction Eprex was continued for another one month after the end of chemotherapy.
When collecting blood before planned major surgery Eprex administered intravenously after blood collection. In this case it is administered two times per week, three weeks in a row, with each visit to the doctor is taken from a portion of the patient blood and maintain it for the same patient transfusion. Eprex dose of 600 IU / kg, two times per week.
Patients who plan the operation, but did not participate in the program of collecting autologous blood and if the operation has already been made, Eprex is injected subcutaneously 600 IU / kg / week, 3 weeks in a row.
Eprex may cause unwanted effects such as dizziness, fever, joint pain and headaches, fatigue, high blood pressure, seizures, allergic reactions such as rash, pruritus, urticaria or angioedema. Local reactions may be related to the injection site, and manifest in the form of a burning sensation, redness, mild pain at the injection site.